The Osteonecrosis drugs in development market research report provides comprehensive information on the therapeutics under development for Osteonecrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Osteonecrosis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Osteonecrosis and features dormant and discontinued products.

GlobalData tracks ten drugs in development for Osteonecrosis by seven companies/universities/institutes. The top development phase for Osteonecrosis is preclinical with six drugs in that stage. The Osteonecrosis pipeline has ten drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Osteonecrosis pipeline products market are: CEFO, Ankasa Regenerative Therapeutics and Xcelia.

The key targets in the Osteonecrosis pipeline products market include Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4), and Low Density Lipoprotein Receptor Related Protein (LRP).

The key mechanisms of action in the Osteonecrosis pipeline product include Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) Agonist with one drug in Phase II. The Osteonecrosis pipeline products include three routes of administration with the top ROA being Parenteral and four key molecule types in the Osteonecrosis pipeline products market including Cell Therapy, and Peptide.

Osteonecrosis overview

Osteonecrosis is bone death caused by poor blood supply to the area. It is most common in the hip and shoulder, but can affect other large joints such as knee, elbow, wrist, and ankle. Osteonecrosis can be caused by disease or a severe trauma, such as a break or dislocation, that affects the blood supply to the bone. There are no symptoms in the early stages. Symptomatic treatment is available.

For a complete picture of Osteonecrosis’s pipeline drug market, buy the report here.

This content was updated on 25 January 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.